EGFR and non-small cell lung carcinoma: Although the application of TKI therapy to patients with EGFR-mutant NSCLC has led to a dramatic lengthening of both progression-free survival (PFS) and overall survival (OS), nearly all patients ultimately progress while receiving EGFR-TKI treatment.